This study evaluates the effects of insulin versus glibenclamide on lipoprotein metabolism at comparable levels of blood glucose control, in particular on the concentration and distribution of VLDL subfractions and lipolytic enzyme activities in nine NIDDM men (aged 56 ± 3 years, BMI 26.5 ± 0.9 kg/m2) (means ± SE) participating in a crossover study. After a 3-week washout period, patients were randomly assigned to 2-month treatment periods (insulin or glibenclamide); thereafter, each patient crossed to the other treatment. At the end of each period, mean daily blood glucose (MDBG), HbA1c, plasma lipids, lipoproteins (VLDL, LDL, HDL), lipoprotein subfractions (VLDL1, 2, 3; HDL2) HDL3), and post-heparin lipase activities (lipoprotein lipase [LPL], hepatic lipase [HL]) were evaluated. Although glucose control was similar at the end of both periods (MDBG 8.3 ± 0.3 vs. 7.9 ± 0.3 mmol/l HbA1c 7.4 ± 0.3 vs. 7.0 ± 0.2%, insulin versus glibenclamide), insulin compared with glibenclamide induced a significant reduction in plasma triglycerides (0.9 ± 0.1 vs. 1.1 ± 0.1 mmoH, P < 0.05), VLDL triglycerides (50.1 ± 12.2 vs. 63.6 ± 12.3 mg/dl, P < 0.02), VLDL1 lipid concentration (24.9 ± 7.5 vs. 39.9 ± 9.5 mg/dl, P < 0.006), and increased HDL2 cholesterol (25.2 ± 1.6 vs. 20.3 ± 1.3 mg/dl, P < 0.03). In terms of VLDL percentage subfraction distribution, with insulin, there was a decrease in the larger subfractions (VLDL1 26.5 ± 3.0 vs. 37.8 ± 3.4%, P < 0.02) and an increase in the smallest (VLDL3 47.3 ± 3.8 vs. 37.3 ± 3.3%, P < 0.05). Moreover, HL activity was significantly lower after insulin than after glibenclamide (HL 247.2 ± 22.3 vs. 263.5 ± 22.6 mU/ml, P < 0.05). In conclusion, compared with glibenclamide, insulin treatment (independent of variations in glucose control) is able to decrease significantly plasma triglycerides, to increase HDL2 cholesterol, and to reduce only the concentration of the larger VLDL subfractions, with a consequent redistribution of their profile.
Skip Nav Destination
Article navigation
Original Articles|
October 01 1997
Insulin and Sulfonylurea Therapy in NIDDM Patients: Are the Effects on Lipoprotein Metabolism Different Even With Similar Blood Glucose Control?
Geremia Romano;
Geremia Romano
Department of Clinical and Experimental Medicine, Federico II University Medical School
Naples
Search for other works by this author on:
Lidia Patti;
Lidia Patti
Department of Clinical and Experimental Medicine, Federico II University Medical School
Naples
Search for other works by this author on:
Francesca Innelli;
Francesca Innelli
Department of Clinical and Experimental Medicine, Federico II University Medical School
Naples
Search for other works by this author on:
Lucrezia Di Marino;
Lucrezia Di Marino
Department of Clinical and Experimental Medicine, Federico II University Medical School
Naples
Search for other works by this author on:
Giovanni Annuzzi;
Giovanni Annuzzi
Department of Clinical and Experimental Medicine, Federico II University Medical School
Naples
Search for other works by this author on:
Gustavo A Coronel;
Gustavo A Coronel
Novo-Nordisk
Rome, Italy
Search for other works by this author on:
Gabriele Riccardi;
Gabriele Riccardi
Department of Clinical and Experimental Medicine, Federico II University Medical School
Naples
Search for other works by this author on:
Angela A Rivellese
Angela A Rivellese
Department of Clinical and Experimental Medicine, Federico II University Medical School
Naples
Search for other works by this author on:
Address correspondence and reprint requests to Dr. A.A. Rivellese, Department of Clinical and Experimental Medicine, Federico II University Medical School of Naples, via S. Pansini, 5, 80131 Naples, Italy.
Diabetes 1997;46(10):1601–1606
Article history
Received:
September 23 1996
Revision Received:
May 09 1997
Accepted:
May 09 1997
PubMed:
9313756
Citation
Geremia Romano, Lidia Patti, Francesca Innelli, Lucrezia Di Marino, Giovanni Annuzzi, Mario Iavicoli, Gustavo A Coronel, Gabriele Riccardi, Angela A Rivellese; Insulin and Sulfonylurea Therapy in NIDDM Patients: Are the Effects on Lipoprotein Metabolism Different Even With Similar Blood Glucose Control?. Diabetes 1 October 1997; 46 (10): 1601–1606. https://doi.org/10.2337/diacare.46.10.1601
Download citation file:
46
Views